查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1873211

全球体外大肠直肠癌筛检测试市场

In-Vitro Colorectal Cancer Screening Tests
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球体外大肠直肠癌筛检市场预计到2030年将达到11亿美元。

全球体外大肠直肠癌筛检市场规模在2024年估计为9.298亿美元，预计到2030年将达到11亿美元，在分析期（2024-2030年）内复合年增长率（CAGR）为3.3%。本报告分析的细分市场之一－大便潜血试验，预计将以3.8%的复合年增长率成长，并在分析期间结束时达到8.815亿美元。生物标记检测细分市场预计在分析期间将以1.5%的复合年增长率成长。

美国市场规模估计为2.482亿美元，而中国市场预计将以5.9%的复合年增长率成长。

预计到2024年，美国体外大肠直肠癌筛检市场规模将达2.482亿美元。作为世界第二大经济体，中国市场预计到2030年将达到2.334亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）为5.9%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为0.5%和4.1%。在欧洲，德国的复合年增长率预计约为1.4%。

全球大肠直肠癌筛检检测（体外诊断）市场—主要趋势与驱动因素摘要

什么是体外大肠直肠癌筛检？它为什么重要？

体外大肠直肠癌筛检是一种诊断工具，用于透过血液、粪便或其他生物检体等非侵入性样本检测大肠直肠癌或其癌前病变。这些检测旨在识别特定的生物标记物，例如DNA突变、血液痕迹或异常蛋白质水平，这些标记可能表明结肠或直肠中存在癌细胞或癌前细胞。由于大肠直肠癌仍然是全球最常见且致死率最高的癌症之一，因此早期发现对于改善患者预后至关重要。体外筛检提供了一种侵入性较小、更易于操作的替代传统大肠镜检查的方法，传统大肠镜检查通常会让患者感到恐惧或不适。这些检测能够在癌症早期阶段（治疗效果最佳的时期）发现癌症，使其成为降低死亡率和提高高风险患者长期存活率的重要工具。

体外大肠癌筛检测试如何改变早期检测的格局？

体外大肠直肠癌筛检检测正在革新早期癌症检测方法，为患者提供更便利、更非侵入性的检测选择。传统方法，例如内视镜检查，虽然高效，但由于其侵入性，常常面临患者的抵抗情绪。相较之下，体外检测透过分析血液或粪便样本来检测癌症征兆，侵入性大大降低，通常可以在家中进行，从而提高了患者的依从性和接受度。大便潜血试验(FIT)、粪便 DNA 检测和血液检测等检测方法简化了筛检流程，使那些不愿意或无法定期接受大肠镜检查的人更容易获得筛检机会。这些检测对于需要定期筛检的高风险族群尤其重要，例如有大肠直肠癌家族病史的人或 50 岁以上的人。由于操作简便，体外检测有助于在症状出现之前，即癌症的早期阶段就发现癌症。这不仅提高了治疗成功率，而且透过早期发现减少了对更具侵入性检查的需求，从而减轻了医疗负担。这些进步正在改变患者照护，使其更加重视预防和主动治疗，使医疗专业人员能够对大肠癌采取更有效、更积极主动的方法。

哪些技术创新正在影响体外大肠癌筛检？

体外大肠直肠癌筛检领域取得了显着的技术进步，尤其是在生物标记检测、分子诊断和自动化方面。其中一项关键进展是次世代定序（NGS）技术的应用，该技术能够对与大肠直肠癌相关的基因突变和DNA改变进行详细分析。 NGS能够同时检测多种基因标记物，从而提高了筛检测试的准确性和可靠性。此外，分析血液中循环肿瘤DNA（ctDNA）的液态生物检体技术已成为早期癌症检测的有力工具，并为监测和筛检提供了微创选择。人工智慧（AI）和机器学习在提高体外检测的敏感度和特异性方面也发挥关键作用。透过分析大型数据集并识别生物标记水平的模式，AI演算法能够提高癌症检测的准确性，并最大限度地减少假阳性和假阴性结果。这优化了筛检流程，确保患者能够及时获得准确的诊断。此外，自动化技术的进步也使这些检测更有效率和扩充性，从而降低了分析成本和所需时间。这一点尤其重要，因为卫生系统正在努力提高大肠癌筛检的普及性和成本效益。

哪些因素推动了体外大肠直肠癌筛检市场的快速成长？

体外大肠直肠癌筛检市场的成长受多种因素驱动，包括人们对早期检测意识的提高、筛检技术的进步以及大肠直肠癌发病率的上升。随着公共卫生宣传活动强调定期癌症筛检的重要性，尤其是在高风险族群中，对非侵入性且便利的检测方法的需求正在激增。与大肠镜检查等传统筛检相比，体外检测为患者提供了创伤较小的选择，其便利性、低成本和较低的不适感使其越来越受欢迎，从而鼓励人们定期筛检。技术创新也是主要驱动力。分子诊断、生物标记发现和液态生物检体技术的创新显着提高了体外检测的灵敏度和特异性，从而提高了其准确性和可靠性。这吸引了以前依赖传统方法的医疗机构和患者，从而扩大了市场。此外，全球人口老化以及大肠癌发生率的上升也推动了对有效早期检测解决方案的需求。随着越来越多的人进入大肠直肠癌高风险年龄组，对便利性、非侵入性筛检工具的需求持续增加。此外，新兴市场监管支援和医疗基础设施的不断完善也进一步推动了市场成长。各国政府和医疗机构正日益将体外大肠癌筛检纳入国家筛检计划，促进其在各地区的推广应用。这些因素共同推动体外大肠直肠癌筛检市场的发展，有助于提高大肠直肠癌的早期检出率，最终改善患者的治疗效果。

部分：

产品类别（大便潜血试验、生物标记检测、CRC DNA筛检试验），最终用途（医院、临床诊断实验室、其他最终用途）

受访公司范例

  • Abbott Laboratories, Inc.
  • Alere, Inc.
  • Beckman Coulter, Inc.
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure, Inc.
  • Novigenix SA
  • Quidel Corporation
  • Sysmex Corporation

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，改变您分析市场和竞争情报的方式。

Global Industry Analysts 并没有依赖通用的 LLM 或查询产业专用的SLM，而是建立了一个由世界各地领域专家精心整理的内容库，包括视讯转录、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

我们最新发布的报告纳入了关税对区域市场的影响，正如全球产业分析师预测的那样，关税将改变企业的竞争地位，而企业的竞争地位将取决于其总部所在地、製造地以及进出口（成品和OEM产品）。这种复杂多变的市场现实将透过微观和宏观市场动态影响竞争对手，包括销货成本增加、盈利下降以及供应链重组。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 亚太其他地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP11160

Global In-Vitro Colorectal Cancer Screening Tests Market to Reach US$1.1 Billion by 2030

The global market for In-Vitro Colorectal Cancer Screening Tests estimated at US$929.8 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$881.5 Million by the end of the analysis period. Growth in the Biomarker Test segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$248.2 Million While China is Forecast to Grow at 5.9% CAGR

The In-Vitro Colorectal Cancer Screening Tests market in the U.S. is estimated at US$248.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$233.4 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global In-Vitro Colorectal Cancer Screening Tests Market - Key Trends and Drivers Summarized

What Are In-Vitro Colorectal Cancer Screening Tests and Why Are They Vital?

In-vitro colorectal cancer screening tests are diagnostic tools used to detect the presence of colorectal cancer or its precursors through non-invasive samples such as blood, stool, or other biological specimens. These tests are designed to identify specific biomarkers, such as DNA mutations, blood traces, or abnormal protein levels, which may indicate the presence of cancerous or pre-cancerous cells in the colon or rectum. As colorectal cancer remains one of the most common and deadly cancers worldwide, early detection is critical to improving patient outcomes. In-vitro screening offers a less invasive, more accessible alternative to traditional colonoscopy, which can often be intimidating or uncomfortable for patients. The ability of these tests to detect cancer at an early stage-when treatment is most effective-makes them a crucial tool in reducing mortality rates and improving long-term survival for patients at risk.

How Are In-Vitro Colorectal Cancer Screening Tests Changing the Game in Early Detection?

In-vitro colorectal cancer screening tests are revolutionizing the approach to early cancer detection by providing easier, more patient-friendly methods of screening. Traditional methods, such as colonoscopy, although highly effective, have often faced resistance from patients due to the invasive nature of the procedure. In contrast, in-vitro tests, which involve analyzing blood or stool samples for signs of cancer, are much less invasive and can often be conducted in the comfort of a patient’s home, enhancing compliance and screening rates. Tests like fecal immunochemical tests (FIT), stool DNA tests, and blood-based assays have simplified the screening process, making it more accessible to populations that are either unwilling or unable to undergo routine colonoscopies. These tests are especially significant for high-risk groups, including those with a family history of colorectal cancer or individuals over the age of 50, who require regular screening. By increasing the ease of screening, in-vitro tests are helping to identify cancer at its earliest stages, before symptoms appear. This not only improves the chances of successful treatment but also lowers the healthcare burden by reducing the need for more invasive procedures when the disease is caught early. With these advancements, patient care is becoming more preventive and less reactive, enabling medical professionals to address colorectal cancer more effectively and proactively.

What Technological Breakthroughs Are Shaping In-Vitro Colorectal Cancer Screening?

The field of in-vitro colorectal cancer screening has seen significant advancements in technology, particularly in the areas of biomarker detection, molecular diagnostics, and automation. One major development is the use of next-generation sequencing (NGS) technology, which enables the detailed analysis of genetic mutations and DNA alterations associated with colorectal cancer. NGS allows for the detection of multiple genetic markers simultaneously, increasing the accuracy and reliability of screening tests. Additionally, liquid biopsy technologies, which analyze circulating tumor DNA (ctDNA) in the bloodstream, are emerging as a powerful tool for early cancer detection, offering a minimally invasive option for monitoring and screening. Artificial intelligence (AI) and machine learning are also playing a critical role in improving the sensitivity and specificity of in-vitro tests. By analyzing large datasets and identifying patterns in biomarker levels, AI-powered algorithms can enhance the precision of cancer detection, minimizing false positives and negatives. This helps in refining the screening process and ensures that patients receive timely and accurate diagnoses. Furthermore, advancements in automation are making these tests more efficient and scalable, reducing the cost and time required for analysis. This is particularly important as healthcare systems strive to make colorectal cancer screening more accessible and cost-effective for widespread use.

What Is Driving the Rapid Growth of the In-Vitro Colorectal Cancer Screening Market?

The growth in the in-vitro colorectal cancer screening market is driven by several factors, including increasing awareness of early detection, advancements in screening technology, and the rising prevalence of colorectal cancer. As public health campaigns emphasize the importance of regular cancer screening, particularly for high-risk individuals, demand for non-invasive and accessible testing methods is surging. In-vitro tests, which provide a more patient-friendly alternative to traditional screening procedures like colonoscopy, are gaining popularity due to their convenience, lower cost, and reduced discomfort, encouraging more people to undergo regular screening. Technological advancements are another key driver. Innovations in molecular diagnostics, biomarker discovery, and liquid biopsy technologies are significantly enhancing the sensitivity and specificity of in-vitro tests, making them more accurate and reliable. This is expanding the market by attracting healthcare providers and patients who previously relied on traditional methods. Additionally, the aging global population, coupled with the increasing incidence of colorectal cancer, is fueling demand for effective early detection solutions. As more people fall into the high-risk age bracket for colorectal cancer, the need for accessible and non-invasive screening tools continues to grow. Moreover, regulatory support and expanding healthcare infrastructure in emerging markets are further contributing to the market’s growth. Governments and healthcare organizations are increasingly endorsing in-vitro colorectal cancer screening as part of national screening programs, driving adoption across various regions. Together, these factors are propelling the in-vitro colorectal cancer screening market forward, helping to improve early detection rates and, ultimately, patient outcomes in the fight against colorectal cancer.

SCOPE OF STUDY:

The report analyzes the In-Vitro Colorectal Cancer Screening Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Fecal Occult Blood Test, Biomarker Test, CRC DNA Screening Test); End-Use (Hospitals, Clinical Diagnostic Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories, Inc.
  • Alere, Inc.
  • Beckman Coulter, Inc.
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure, Inc.
  • Novigenix SA
  • Quidel Corporation
  • Sysmex Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • In-Vitro Colorectal Cancer Screening Tests - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Colorectal Cancer Propels Growth in In-Vitro Screening Test Demand
    • Technological Advancements in Biomarker Detection Strengthen Business Case for Early Diagnosis
    • Shift Towards Non-invasive Diagnostic Techniques Expands Addressable Market for In-Vitro Colorectal Cancer Tests
    • Aging Population Spurs Growth of Colorectal Cancer Screening, Driving Demand for Advanced In-Vitro Diagnostics
    • Increased Consumer Preference for At-home Testing Solutions Generates Demand for Convenient Screening Options
    • Advances in Molecular Diagnostics Throws the Spotlight on Personalized Medicine and Targeted Screening
    • Rising Adoption of Liquid Biopsy Techniques Propels Innovation and Expansion in Screening Solutions
    • Increased Integration of AI and Machine Learning in Diagnostic Tools Drives Accuracy in Test Outcomes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World In-Vitro Colorectal Cancer Screening Tests Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Fecal Occult Blood Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Biomarker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for CRC DNA Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION